Knight Therapeutics (GUD) M&A Announcement summary

Deal rationale and strategic fit

• Acquisition reunites two businesses previously separated, leveraging shared history and leadership vision, and adds critical mass to expand the Canadian footprint.

• Adds a portfolio of stable, cash-generating pharmaceuticals to support growth in Canada and Latin America.

• Enhances presence in key therapeutic areas, notably neurology and hospital products.

• Provides a platform for further launches and team expansion in Canada.

Financial terms and conditions

• Upfront payment of CAD 100 million plus CAD 20 million for inventory, payable in cash at closing, totaling CAD 120 million.

• Up to $15 million in contingent payments tied to sales milestones.

• Funded entirely with cash and marketable securities on hand.

• No debt assumed; asset acquisition structure.

• Paladin generated $70 million in 2024 revenues, excluding discontinued products.

Synergies and expected cost savings

• Efficiencies and synergies expected, especially in Canadian operations, over the next year.

• Acquisition of personnel reduces need for additional hires, supporting growth with fewer incremental resources.